Allogene Therapeutics, Inc. (ALLO) stock
ALLONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.83−0.07 (-8.12%)
Close on Nov 12, 2026Market cap $285.72MP/E –Yield 0.00%
Allogene Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Allogene Therapeutics's total assets was $511.32M at Sep 30, 2026. For fiscal 2025 it was $415.91M, down 24.2% from the year before. The highest annual figure on record is $1.23B in fiscal 2020.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $415.91M | -24.2% |
| FY2024 | Dec 31, 2024 | $548.71M | -14.6% |
| FY2023 | Dec 31, 2023 | $642.84M | -21.8% |
| FY2022 | Dec 31, 2022 | $821.58M | -21.8% |
| FY2021 | Dec 31, 2021 | $1.05B | -14.4% |
| FY2020 | Dec 31, 2020 | $1.23B | +71.1% |
| FY2019 | Dec 31, 2019 | $717.80M | -7.2% |
| FY2018 | Dec 31, 2018 | $773.86M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $511.32M | +16.3% |
| Q2 FY2026 | Jun 30, 2026 | $550.09M | +16.9% |
| Q1 FY2026 | Mar 31, 2026 | $395.96M | -22.1% |
| Q4 FY2025 | Dec 31, 2025 | $415.91M | -24.2% |
| Q3 FY2025 | Sep 30, 2025 | $439.77M | -25.4% |
| Q2 FY2025 | Jun 30, 2025 | $470.59M | -27.3% |
| Q1 FY2025 | Mar 31, 2025 | $507.98M | -13.4% |
| Q4 FY2024 | Dec 31, 2024 | $548.71M | -14.6% |
| Q3 FY2024 | Sep 30, 2024 | $589.12M | -17.4% |
| Q2 FY2024 | Jun 30, 2024 | $646.88M | -16.3% |
| Q1 FY2024 | Mar 31, 2024 | $586.35M | -21.8% |
| Q4 FY2023 | Dec 31, 2023 | $642.84M | -21.8% |
| Q3 FY2023 | Sep 30, 2023 | $713.41M | -20.2% |
| Q2 FY2023 | Jun 30, 2023 | $773.01M | -19.1% |
| Q1 FY2023 | Mar 31, 2023 | $750.13M | -23.3% |
| Q4 FY2022 | Dec 31, 2022 | $821.58M | -21.8% |
| Q3 FY2022 | Sep 30, 2022 | $894.48M | -17.1% |
| Q2 FY2022 | Jun 30, 2022 | $955.62M | -15.2% |
| Q1 FY2022 | Mar 31, 2022 | $978.09M | -17.0% |
| Q4 FY2021 | Dec 31, 2021 | $1.05B | -14.4% |
| Q3 FY2021 | Sep 30, 2021 | $1.08B | -11.7% |
| Q2 FY2021 | Jun 30, 2021 | $1.13B | -10.5% |
| Q1 FY2021 | Mar 31, 2021 | $1.18B | +71.2% |
| Q4 FY2020 | Dec 31, 2020 | $1.23B | +71.1% |
| Q3 FY2020 | Sep 30, 2020 | $1.22B | +75.8% |
| Q2 FY2020 | Jun 30, 2020 | $1.26B | +71.5% |
| Q1 FY2020 | Mar 31, 2020 | $688.52M | -8.1% |
| Q4 FY2019 | Dec 31, 2019 | $717.80M | -7.2% |
| Q3 FY2019 | Sep 30, 2019 | $695.54M | +59.8% |
| Q2 FY2019 | Jun 30, 2019 | $734.00M | – |
| Q1 FY2019 | Mar 31, 2019 | $749.37M | – |
| Q4 FY2018 | Dec 31, 2018 | $773.86M | – |
| Q3 FY2018 | Sep 30, 2018 | $435.24M | – |
See a number that looks wrong?